ABSTRACT
Background: New Classification of Periodontal and Peri-implant Diseases and Conditions having worked into 2017 has defined candida-associated periodontal lesions as “Non-plaque-induced gingival diseases” associated with specific infection (list point 2.3). Patients with diagnosis Periodontal candidosis have been observed at the Division of Periodontology SPBGMU and City Periodontal Center “PAKS” more than for 25 years with an average quantity of 3-5 new cases a year. There had been formed a typical pattern for setting diagnosis and treatment. As a risk group was recognized, patients who predominantly had such general conditions as diabetes, immunosuppressive therapy, and heavy smokers. Since 2020 the pattern has been completely changed due to changing general conditions of the patients who consisted of the group and increasing quantity of periodontal candidosis about threefold. The core of the group has consisted of predominantly patients who recently had COVID-19 and/or underwent immunosuppressive therapy. Description of the procedure: Diagnostic procedure: Level 1. Anamnesis, clinical record, standard periodontal charting, estimation of periodontal and hygienical indices, absence or present mucosa lesions. CBCT Level 2. Clinical fluorescence diagnostic-wave length 400 ± 10 nm estimation gingival and mucosa condition. The cultural test for Candida detecting. Level 3. Cytology Treatment: in addition to SRP procedure there prescribed local and systemic antifungal therapy. 1. Photodynamic therapy (toluidine blue photosensitizer) 2. Local antifungal therapy - rinsing by Clotrimazole solution 3. Systemic antifungal therapy - Fluconazole 150 mg once in day 4. Modification of host response - Imudon 6 six in day 5. Toothpaste with the alkalic antifungal agent -sodium bicarbonate. Outcomes: Outcome control: Clinical investigation, the cultural test for Candida. Case: Female age 47 had a severe COVID-19 case, 3 months later she had rising level of activity periodontitis without response on usual periodontal therapy. Conclusions: Candida-associated periodontitis is difficult for diagnostic and treatment disease which use to occur quietly rare but nowadays have vastly increased.
ABSTRACT
Drug repurposing is the remodeling of already existing drugs to reduce the time frame, costs, and efforts in developing a new novel drug. This strategy has secured significant momentum in the previous decade. It overcomes the snags and pitfalls in the traditional means of drug discovery. This core research strategy has now become the sole approach to containing many deadly diseases that have no cure in the present. In astound, for pandemics like COVID-19 that is spreading like a wildfire worldwide, large-scale research programs and trials have been carried out to identify and modify existing drugs to counter the novel virus. Thus, this technology of drug repurposing offers a new lease of life, and greatly promotes the progress of the medicine, health, and pharma sectors. The purpose of this study is to understand the current status of drug repurposing in the field of virology, bacteriology, mycology, and oncology for clinical translatability.